{"id":45312,"date":"2022-06-21T16:01:39","date_gmt":"2022-06-21T14:01:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/"},"modified":"2022-06-21T16:01:39","modified_gmt":"2022-06-21T14:01:39","slug":"insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/","title":{"rendered":"Insight Partners with Global Nonprofit Vivli on First-Ever Industry Antimicrobial Resistance Research Platform"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Clinical research initiative combats global threats to public health by accelerating data sharing on infection-causing pathogens and antibiotic resistance<\/i>\n<\/p>\n<p>CHANDLER, Ariz.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.insight.com%2F&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=Insight+Enterprises&amp;index=1&amp;md5=535758c1be18031203270dea148bd045\" rel=\"nofollow noopener\" shape=\"rect\">Insight Enterprises<\/a> (NASDAQ:NSIT), a Fortune 500 solutions integrator helping clients accelerate their digital journey, announced today that it has worked with <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvivli.org%2F&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=Vivli&amp;index=2&amp;md5=596caa47f00046dd37572efd63725f7b\" rel=\"nofollow noopener\" shape=\"rect\">Vivli<\/a>, a nonprofit dedicated to advancing human health through clinical research data sharing, to support the launch of Vivli\u2019s <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amr.vivli.org%2F&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=Antimicrobial+Resistance+Register&amp;index=3&amp;md5=82a1490f8a0cdab87b3d51f74e4d803d\" rel=\"nofollow noopener\" shape=\"rect\">Antimicrobial Resistance Register<\/a> (AMR Register). The revolutionary, global platform allows biopharmaceutical companies to share susceptibility data on infection-causing pathogens.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220621005498\/en\/703500\/5\/Insight_Logo_Med.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220621005498\/en\/703500\/21\/Insight_Logo_Med.jpg\"><\/a><\/p>\n<p>\n\u201cThe launch of the AMR Register platform marks a critical step in combating the growing global health threat of antimicrobial resistance, in which illnesses that were once easily treatable with antibiotics are becoming more difficult to cure,\u201d said Vivli Executive Director Rebecca Li, PhD. \u201cThe support of Insight\u2019s technology solutions and deep technical expertise was integral in Vivli\u2019s efforts building the AMR Register, which can help researchers securely access critical raw data, combine and analyze multiple datasets from across the industry, contain the risk of antimicrobial resistance and, ultimately, advance scientific knowledge.\u201d\n<\/p>\n<p>\nThe launch of Vivli\u2019s AMR Register is the first single, streamlined online platform to promote open sharing of industry surveillance data and will support researchers in their efforts to:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIdentify global, regional and local changes in resistance rates of pathogens;\n<\/li>\n<li>\nDetect trends in multi-drug resistance by analyzing data over time and enable modelling of future resistance trends;\n<\/li>\n<li>\nCatalyze innovation around new antimicrobial drugs; and\n<\/li>\n<li>\nHelp inform national and international policy and antibiotic stewardship.\n<\/li>\n<\/ul>\n<p>\n\u201cResearch insights that are informed by <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fsolutions.insight.com%2FSolutions%2FData-and-AI%2FData-Platforms&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=reliable%2C+robust+data+ecosystems&amp;index=4&amp;md5=aa576065e60d8529e8ec9a7f445264eb\" rel=\"nofollow noopener\" shape=\"rect\">reliable, robust data ecosystems<\/a> are hugely important across the healthcare industry, as well as pharmaceutical and biotech enterprises, who are working to control antimicrobial resistant infections and protect human health,\u201d said Stan Lequin, senior vice president and general manager, Solutions, Insight. \u201cInnovation like the AMR Register fills that gap in data translation and can spur meaningful action that has the potential to save lives as Vivli works to curtail one of the top global public health threats. We are proud to support Vivli\u2019s work and vision preserving antibiotics for \u2014 and protecting the health of \u2014 future generations worldwide.\u201d\n<\/p>\n<p>\nInsight has been the nonprofit\u2019s long-standing technical development and platform maintenance partner, supporting <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.insight.com%2Fnews-releases%2Fnews-release-details%2F2020%2FInsight-Helps-Vivli-Launch-COVID-19-Portal%2Fdefault.aspx&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=Vivli%26%238217%3Bs+launch&amp;index=5&amp;md5=3c652fd4928f6ac14b68daad8ad3ff7b\" rel=\"nofollow noopener\" shape=\"rect\">Vivli\u2019s launch<\/a> of its Covid-19 data sharing portal in April 2020 and its <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvivli.org%2Finnovative-global-data-sharing-platform-vivli-launches-with-2500-clinical-studies%2F&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=global+clinical+trial+research+platform&amp;index=6&amp;md5=461252c31e6d36435284e4b8c1e54091\" rel=\"nofollow noopener\" shape=\"rect\">global clinical trial research platform<\/a> in 2018.\n<\/p>\n<p>\nThe AMR Register is guided by a Scientific Advisory Board of influential leaders in antimicrobial resistance and global health, including <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Famr.vivli.org%2Fteam%2Fdr-henry-kajumbula%2F&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=Henry+Kajumbula&amp;index=7&amp;md5=8fa69c5b55d9a471db9a91ace0466fb1\" rel=\"nofollow noopener\" shape=\"rect\">Henry Kajumbula<\/a>, MD of Makerere University College of Health Sciences; <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Famr.vivli.org%2Fteam%2Fprofessor-trudie-lang%2F&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=Trudie+Lang&amp;index=8&amp;md5=b330b215b2e5947363e6a5dc672bad11\" rel=\"nofollow noopener\" shape=\"rect\">Trudie Lang<\/a> of the Nuffield Department of Medicine; Marc Mendelson, PhD, of Groote Schuur Hospital, University of Cape Town; Arjun Srinivasan, MD, from the Centers for Disease Control and Prevention; Janet Midega, PhD, from Wellcome; and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Famr.vivli.org%2Fteam%2Fdr-andy-stergachis%2F&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=Andy+Stergachis&amp;index=9&amp;md5=d18869a410ebb60410253e1adbf7722a\" rel=\"nofollow noopener\" shape=\"rect\">Andy Stergachis<\/a>, PhD, of the University of Washington. The AMR Register was made possible with an initial seed grant from the Wellcome Trust.\n<\/p>\n<p>\nFor more information on Vivli\u2019s AMR Register, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Famr.vivli.org%2F&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=amr.vivli.org&amp;index=10&amp;md5=b9d1c78f84e5c34fd2252d9323425445\" rel=\"nofollow noopener\" shape=\"rect\">amr.vivli.org<\/a>.\n<\/p>\n<p>\nFor more information on Insight, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.insight.com%2F%3Futm_medium%3Dpr%26utm_source%3Dnews%26utm_campaign%3DNews_Release&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=insight.com&amp;index=11&amp;md5=a6b6d936fc9b0ef90be1377fa189af23\" rel=\"nofollow noopener\" shape=\"rect\">insight.com<\/a> or call 800-INSIGHT.\n<\/p>\n<p>\n<b>About Insight<\/b>\n<\/p>\n<p>\nInsight Enterprises, Inc. is a Fortune 500 solutions integrator with more than 11,500 teammates worldwide helping organizations accelerate their digital journey to modernize their business and maximize the value of technology. We enable secure, end-to-end transformation and meet the needs of our clients through a comprehensive portfolio of solutions, far-reaching partnerships and 33+ years of broad IT expertise. Rated as a Forbes World\u2019s Best Employer and a Great Place to Work, we amplify our solutions and services with global scale, local expertise and a world-class e-commerce experience, realizing the digital ambitions of our clients at every opportunity. Discover more at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.insight.com%2F&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=insight.com&amp;index=12&amp;md5=98e4aee7a8ad87de5d22a8154089218d\" rel=\"nofollow noopener\" shape=\"rect\">insight.com<\/a>. NSIT-M\n<\/p>\n<p>\n<b>About Vivli<\/b>\n<\/p>\n<p>\nVivli is a nonprofit organization working to advance human health through the insights and discoveries gained by sharing and analyzing data. Data sharing initiatives include the <i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amr.vivli.org&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=Antimicrobial+Resistance+Register&amp;index=13&amp;md5=16ac32cd872bda13823a08eb2cd826a0\" rel=\"nofollow noopener\" shape=\"rect\">Antimicrobial Resistance Register<\/a><\/i><i> <\/i>for AMR surveillance data and the<i> <\/i><i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vivli.org%2F&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=Vivli+Platform&amp;index=14&amp;md5=002bdf6b744fd1124e340fc270e0420b\" rel=\"nofollow noopener\" shape=\"rect\">Vivli Platform<\/a><\/i><i> <\/i>for clinical trial data. Vivli acts as a neutral broker between data contributor and data user and the wider data sharing community. For more information, visit<i> <\/i><i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vivli.org&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=www.vivli.org&amp;index=15&amp;md5=428d84e3d4d39f779433b9ef30af6b01\" rel=\"nofollow noopener\" shape=\"rect\">www.vivli.org<\/a><\/i><i> <\/i>and follow us on Twitter<i> <\/i><i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fvivlicenter&amp;esheet=52756314&amp;newsitemid=20220621005498&amp;lan=en-US&amp;anchor=%40VivliCenter&amp;index=16&amp;md5=b786fbe710db3cf56e3099cef59ae3cd\" rel=\"nofollow noopener\" shape=\"rect\">@VivliCenter<\/a><\/i><i>.<\/i>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Scott Walters<\/b><br \/>Insight Enterprises<br \/>\n<br \/>Tel. (480) 889-9798<br \/>\n<br \/>Email: <a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x73;&#x63;&#x6f;&#x74;&#x74;&#x2e;&#x77;&#x61;&#x6c;&#x74;&#x65;&#x72;&#x73;&#x40;&#x69;&#x6e;&#x73;&#x69;&#x67;&#x68;&#x74;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x73;&#x63;&#x6f;&#x74;&#116;&#46;wal&#x74;&#x65;&#x72;&#x73;&#64;&#105;nsi&#x67;&#x68;&#x74;&#x2e;&#99;&#111;&#109;<\/a>\n<\/p>\n<p>\n<b>Ariel Kouvaras<\/b><br \/>Sloane &amp; Co.<br \/>\n<br \/>Tel. (212) 446-1884<br \/>\n<br \/>Email: <a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#111;&#x3a;&#97;&#x6b;o&#x75;v&#97;&#x72;&#97;&#x73;&#64;&#x73;&#x6c;&#111;&#x61;n&#x65;p&#114;&#x2e;&#99;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#97;&#x6b;&#x6f;&#117;&#x76;&#x61;&#114;&#x61;&#x73;&#64;&#x73;&#x6c;&#111;&#x61;&#x6e;&#101;&#x70;&#x72;&#46;&#x63;&#x6f;&#109;<\/a>\n<\/p>\n<p>\n\u00a0\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Clinical research initiative combats global threats to public health by accelerating data sharing on infection-causing pathogens and antibiotic resistance CHANDLER, Ariz.&#8211;(BUSINESS WIRE)&#8211;Insight Enterprises (NASDAQ:NSIT), a Fortune 500 solutions integrator helping clients accelerate their digital journey, announced today that it has worked with Vivli, a nonprofit dedicated to advancing human health through clinical research data sharing, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45312","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Insight Partners with Global Nonprofit Vivli on First-Ever Industry Antimicrobial Resistance Research Platform - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insight Partners with Global Nonprofit Vivli on First-Ever Industry Antimicrobial Resistance Research Platform - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Clinical research initiative combats global threats to public health by accelerating data sharing on infection-causing pathogens and antibiotic resistance CHANDLER, Ariz.&#8211;(BUSINESS WIRE)&#8211;Insight Enterprises (NASDAQ:NSIT), a Fortune 500 solutions integrator helping clients accelerate their digital journey, announced today that it has worked with Vivli, a nonprofit dedicated to advancing human health through clinical research data sharing, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-21T14:01:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220621005498\/en\/703500\/21\/Insight_Logo_Med.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Insight Partners with Global Nonprofit Vivli on First-Ever Industry Antimicrobial Resistance Research Platform\",\"datePublished\":\"2022-06-21T14:01:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\\\/\"},\"wordCount\":714,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621005498\\\/en\\\/703500\\\/21\\\/Insight_Logo_Med.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\\\/\",\"name\":\"Insight Partners with Global Nonprofit Vivli on First-Ever Industry Antimicrobial Resistance Research Platform - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621005498\\\/en\\\/703500\\\/21\\\/Insight_Logo_Med.jpg\",\"datePublished\":\"2022-06-21T14:01:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621005498\\\/en\\\/703500\\\/21\\\/Insight_Logo_Med.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621005498\\\/en\\\/703500\\\/21\\\/Insight_Logo_Med.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insight Partners with Global Nonprofit Vivli on First-Ever Industry Antimicrobial Resistance Research Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Insight Partners with Global Nonprofit Vivli on First-Ever Industry Antimicrobial Resistance Research Platform - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/","og_locale":"en_US","og_type":"article","og_title":"Insight Partners with Global Nonprofit Vivli on First-Ever Industry Antimicrobial Resistance Research Platform - Pharma Trend","og_description":"Clinical research initiative combats global threats to public health by accelerating data sharing on infection-causing pathogens and antibiotic resistance CHANDLER, Ariz.&#8211;(BUSINESS WIRE)&#8211;Insight Enterprises (NASDAQ:NSIT), a Fortune 500 solutions integrator helping clients accelerate their digital journey, announced today that it has worked with Vivli, a nonprofit dedicated to advancing human health through clinical research data sharing, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-21T14:01:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220621005498\/en\/703500\/21\/Insight_Logo_Med.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Insight Partners with Global Nonprofit Vivli on First-Ever Industry Antimicrobial Resistance Research Platform","datePublished":"2022-06-21T14:01:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/"},"wordCount":714,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220621005498\/en\/703500\/21\/Insight_Logo_Med.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/","url":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/","name":"Insight Partners with Global Nonprofit Vivli on First-Ever Industry Antimicrobial Resistance Research Platform - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220621005498\/en\/703500\/21\/Insight_Logo_Med.jpg","datePublished":"2022-06-21T14:01:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220621005498\/en\/703500\/21\/Insight_Logo_Med.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220621005498\/en\/703500\/21\/Insight_Logo_Med.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/insight-partners-with-global-nonprofit-vivli-on-first-ever-industry-antimicrobial-resistance-research-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Insight Partners with Global Nonprofit Vivli on First-Ever Industry Antimicrobial Resistance Research Platform"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45312"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45312\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}